Clinical Trial Detail

NCT ID NCT02374099
Title Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant
Recruitment Terminated
Gender female
Phase Phase II
Variant Requirements yes
Sponsors Celgene Corporation
Indications

Her2-receptor negative breast cancer

Therapies

Azacitidine

Fulvestrant

Age Groups: adult

Additional content available in CKB BOOST